News|Articles|November 18, 2026

Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML

Author(s)Jonah Feldman
Fact checked by: Sabrina Serani
Listen
0:00 / 0:00

Key Takeaways

  • Median overall survival was 24.0 months with galinpepimut-S versus 14.7 months with best available treatment, corresponding to a 41% relative reduction in mortality risk (HR 0.59).
  • REGAL enrolled AML patients in CR2/CRp2 or later after ≥2nd-line salvage who were unable to proceed to allogeneic transplant; randomization was stratified by MRD, cytogenetics, and remission features.
SHOW MORE

Galinpepimut-S maintenance improved median OS to 24.0 vs 14.7 months with best available treatment in AML in second remission, a 41% reduction in risk of death.

Maintenance therapy with the investigational WT1-targeted peptide vaccine galinpepimut-S (GPS) significantly extended overall survival (OS) vs best available treatment (BAT) in patients with acute myeloid leukemia (AML) in second or later remission who could not undergo allogeneic stem cell transplantation.1

According to the topline results from the phase 3 REGAL trial (NCT04229979), median OS was 24.0 months with galinpepimut-S vs 14.7 months with BAT (HR, 0.59; 2-sided P =.035), translating to a 41% reduction in risk of death. The analysis was triggered by the prespecified 80th OS event.

“Patients with AML in second remission who cannot undergo allogeneic stem cell transplantation face poor survival outcomes and have a significant need for new treatment approaches,” said members of the REGAL Study Steering Committee, chaired by Hagop M. Kantarjian, MD, professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center and global principal investigator of the trial, in a news release.

REGAL Trial Design

Galinpepimut-S comprises 4 WT1-derived peptides intended to elicit CD4-positive and CD8-positive T-cell responses across multiple human leukocyte antigen types.

REGAL is a global, open-label, randomized registrational study that enrolled patients with AML who reached a second or later complete remission, or complete remission with incomplete platelet recovery, following at least second-line salvage therapy, provided they could not receive or proceed to allogeneic transplant.

A total of 126 patients were randomly assigned 1:1 to galinpepimut-S monotherapy or to investigator’s choice of BAT, which could include observation, a hypomethylating agent, venetoclax (Venclexta), and/or low-dose cytarabine. OS from study entry is the primary end point. Secondary end points include safety, leukemia-free survival, landmark OS, relapse-free survival in patients with a prior allogeneic transplant, antigen-specific T-cell responses, and measurable residual disease.1 Randomization was stratified by remission type, cytogenetic risk, measurable residual disease status, and duration of first complete remission.2

Safety of Galinpepimut-S

Treatment-related adverse events were mostly grade 1 or 2 and most often local injection site reactions, and no new safety signals emerged. The arms were balanced for prognostic stratification factors, and few patients went on to transplant, with similar numbers in each arm.1

Analyses of secondary and other prespecified end points are underway and that full results will be presented at an upcoming medical meeting and submitted for publication.

Prior REGAL Data and Regulatory Plans

At an interim analysis triggered by 60 deaths, the independent data monitoring committee recommended that REGAL continue without modification after galinpepimut-S cleared the prespecified futility threshold, and no safety concerns were identified. The FDA granted galinpepimut-S rare pediatric disease designation for pediatric AML in October 2024.3

SELLAS Life Sciences, the sponsor, plans to meet with the FDA to discuss an accelerated filing strategy and is preparing a biologics license application, with submission targeted for the first half of 2027.1

“Given the significant unmet need in this patient population, we look forward to engaging with the FDA to discuss the results and the regulatory path forward, with the goal of making this therapy available to patients as rapidly as possible,” Angelos Stergiou, MD, ScD h.c., president and CEO of SELLAS Life Sciences, stated in the news release.1

REFERENCES
1. SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia. News release. SELLAS Life Sciences Group. November 17, 2026. Accessed November 17, 2026. https://tinyurl.com/mt9xna7y
2. Galinpepimut-S versus investigator's choice of best available therapy for maintenance in AML CR2/​CRp2 (REGAL). ClinicalTrials.gov. Updated April 9, 2024. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT04229979
3. SELLAS Life Sciences announces positive outcome of interim analysis for its pivotal phase 3 REGAL trial of GPS in acute myeloid leukemia. News release. SELLAS Life Sciences Group, Inc. January 23, 2025. Accessed January 23, 2025. https://tinyurl.com/2n7kz8wb

Related to this article